Napredna pretraga

Pregled bibliografske jedinice broj: 759294

PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER RENAL TRANSPLANTATION - A SINGLE CENTER EXPERIENCE


Anić, Kata; Mikolašević, Ivana; Orlić, Lidija; Devčić, Bosiljka; Nedeljković, Lela; Večerina, Matija; Jakopčić, Ivan; Rački, Sanjin
PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER RENAL TRANSPLANTATION - A SINGLE CENTER EXPERIENCE // Knjiga sažetaka ; 4th Congress of Nephrology of Bosnia and Herzegovina with international participation / Enisa Mesić (ur.).
Sarajevo, 2015. str. 90-90 (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER RENAL TRANSPLANTATION - A SINGLE CENTER EXPERIENCE

Autori
Anić, Kata ; Mikolašević, Ivana ; Orlić, Lidija ; Devčić, Bosiljka ; Nedeljković, Lela ; Večerina, Matija ; Jakopčić, Ivan ; Rački, Sanjin

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Knjiga sažetaka ; 4th Congress of Nephrology of Bosnia and Herzegovina with international participation / Enisa Mesić - Sarajevo, 2015, 90-90

Skup
4th Congress of Nephrology of Bosnia and Herzegovina with international participation

Mjesto i datum
Sarajevo, BIH, 22.-25.travnja, 2015

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
CMV; transplantacija
(CMV; transplantation)

Sažetak
INTRODUCTION: According to the current guidelines prophylactic treatment for Cytomegalovirus (CMV) is recommended in solid organ transplantation. We were interested to explore the prevalence of CMV viremia/disease due to use of prophylactic treatment in our renal transplant recipients (RTRs). METHODS: We retrospectively examined the 24-year (1990-2014) data of 521 RTRs mean age 48.9±13.6 years. On the pretransplant CMV antibody assay, prophylaxis for CMV disease is performed for the following donor/recipient subgroups: Donor (D)+ and Recipient (R)+, D+/ R- and D-/R+. The dose of valacyclovir was adjusted according to renal function. RESULTS: 95 RTRs were received prophylaxis for CMV and 426 patients didn’t received prophylactic treatment. Prophylactic treatment significantly reduced the incidence of CMV disease during the first-year after transplantation (8.45% vs. 2.1% ; p=0.05). Although the prevalence of CMV viremia was higher in the group of patients that didn’t received prophylaxis, that difference was not statistically significant (9.6% vs. 3.2% ; p=0.07). The mean values of serum creatinine didn’t showed any significant differences after one-year of follow-up between the RTRs who had received prophylaxis in comparison to the patients that didn’t received prophylactic treatment (127.7±65.2 vs. 145.1±87 ; p=0.09). In the group of patients that didn’t received prophylactic treatment 15.5% of patients loss their graft during the first year after transplantation, while in the group of patients with prophylactic treatment 6.3% of RTRs loss their graft in the same period. In the group of patients that had received prophylaxis the main reasons for graft loss were an acute rejection (6.1%) and surgical complications (4.9%), while surgical complications (3.2%) and chronic allograft nephropathy (2.1%) were the most common reasons for graft loss in the second group of RTRs. There were no significant differences in the one-year patients survival between the two groups of patients (p=NS). CONCLUSION: Prophylactic treatment for CMV is an effective way to prevent CMV disease after renal transplantation.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove
Medicinski fakultet, Rijeka,
Klinički bolnički centar Osijek,
Klinički bolnički centar Rijeka